Current Helicobacter pylori treatment in 2014

查看全文 作　　者：Fatih [1]Ermis;Elif Senocak [2]Tasci

机构地区：[1]Department of Gastroenterology,Duzce University Faculty of Medicine;[2]Department of Internal Medicine,Duzce University Faculty of Medicine

出　　处：《World Journal of Methodology》索引2015年第5卷第2期,共7页

摘　　要：Helicobacter pylori is one of the most commonly seen bacterium worldwide.It's in the etiology of multiple gastrointestinal diseases,ranging from gastritis to gastric carcinoma.The antimicrobial therapies,which are frequently prescribed empirically,are losing their effectivity as a result of the increasing antimicrobial resistance.As the standard triple therapy is now leftespecially in areas with high-clarithromycin resistance due to decreased eradication rates,quadruple therapies are recommended in most regions of the world.Alternatively,concomitant,sequential and hybrid therapies are used.There is still a debate going on about the use of levofloxacin-based therapy in order to prevent the increase in quinolone resistance.If no regimen can achieve the desired eradication rate,culture-guided individualized therapies are highly recommended.Probiotics,statins and n-acetylcysteine are helpful as adjuvant therapies in order to increase the effectiveness of the eradication therapy.Herein,we focused on different eradication regimens in order to highlight the current Helicobacter pylori treatment. 关键词：Helicobacter pylori ERADICATION TREATMENT Bismuth-quadruple therapy Sequential therapy Concomitant therapy Hybrid therapy

相关文献

参考文献（57）
引证文献（3）
耦合文献（0）

参考文献(57)

引证文献(3)

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

Current Helicobacter pylori treatment in 2014

参考文献(57)

引证文献(3)

用户提示